ArticleJournal of microbiology and biotechnology2021
Purification and Characterization of a Thrombolytic Enzyme Produced by a New Strain of
Article in Journal of microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Enzymatic Properties and Multifunctional Applications of a Novel Extracellular Cold-Active Alkaline Protease from Stenotrophomonas maltophilia Strain TK-4.Applied biochemistry and biotechnology · 2026Article
- Statistical optimization of fermentation conditions for enhanced production of Nattokinase from Bacillus subtilis MM26.BMC biotechnology · 2026Article
- Enhanced nattokinase production by optimized fermentation conditions of douchi-derived Bacillus subtilis natto NK11 and evaluation of its thrombolytic activity.Antonie van Leeuwenhoek · 2025Article
- Characterization and In Vitro Probiotic Assessment ofFood science & nutrition · 2025Article
- Comprehensive biochemical, molecular and structural characterization of subtilisin with fibrinolytic potential in bioprocessing.Bioresources and bioprocessing · 2025Article
- The living medicine inside us:Gut microbes reports · 2025Article
- Biochemical characterization of immobilized recombinant subtilisin and synthesis and functional characterization of recombinant subtilisin capped silver and zinc oxide nanoparticles.Saudi journal of biological sciences · 2024Article
- Maggot Kinase and Natural Thrombolytic Proteins.ACS omega · 2024Review
- Partial Purification and Biochemical Evaluation of Protease Fraction (MA-1) fromAntioxidants (Basel, Switzerland) · 2023Article
- Microbial Fibrinolytic Enzymes as Anti-Thrombotics: Production, Characterisation and Prodigious Biopharmaceutical Applications.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrinolytic enzymes with a direct mechanism of action and safer properties are currently requested for thrombolytic therapy. This paper reports on a new enzyme capable of degrading blood clots directly without impairing blood coagulation. This enzyme is also non-cytotoxic and constitutes an alternative to other thrombolytic enzymes known to cause undesired side effects. Twenty-four
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.